Related Experiment Videos
High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance
M Basta1, P F Langlois, M Marques
1Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Blood
|July 1, 1989
Summary
High-dose intravenous immunoglobulin (IVIG) therapy may work by altering complement deposition on erythrocytes, not just Fc receptor competition. This suggests new uses for IVIG in complement-mediated diseases.
Area of Science:
- Immunology
- Hematology
Background:
- The mechanism of high-dose intravenous immunoglobulin (IVIG) in immune cytopenias is not fully understood.
- A leading theory involves IVIG competing for Fc receptors, inhibiting IgG-mediated clearance.
Purpose of the Study:
- To investigate an alternative mechanism of IVIG action independent of Fc receptor interactions.
- To explore IVIG's effect on complement-dependent clearance pathways.
Main Methods:
- Guinea pigs received high-dose IVIG (600 mg/kg/day for two days).
- Clearance of IgM-sensitized erythrocytes was measured.
- Complement component levels (C3, CH50) and in vitro C3 uptake were assessed.
- Control groups received saline or albumin.
Main Results:
- High-dose IVIG significantly retarded the clearance of complement-dependent IgM-sensitized erythrocytes.
- This effect was specific to IVIG, as albumin had no impact.
- IVIG treatment did not alter C3 or CH50 levels.
- In vitro studies suggested IVIG alters C3 uptake and complement fragment deposition on erythrocytes.
Conclusions:
- High-dose IVIG may exert its effects by modulating complement activation and deposition on erythrocytes.
- This provides a novel mechanism of IVIG action beyond Fc receptor blockade.
- Findings suggest potential for IVIG in treating complement-mediated diseases.